Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Phenylketonuria · Amyotrophic Lateral Sclerosis · PTCT

PTC THERAPEUTICS

PTC THERAPEUTICS, INC.

PTC THERAPEUTICS clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
500 Warren Corporate Center Drive, Warren, NJ 07059, US HQ
1998 Founded
1,153 Employees
Public company Type
PTCT · NYSE Ticker
Company details
Status
Public
HQ
500 Warren Corporate Center Drive, Warren, NJ 07059, US
Founded
1998
Employees
1,153
Programs
52
Drugs
21
Patents
149
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

PTC THERAPEUTICS projects

17 ClinicalTrials.gov programs sponsored by PTC THERAPEUTICS.

PTC THERAPEUTICS has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

17 programs

Clinical programs

  1. Ataluren

    PTC THERAPEUTICS, INC.

    Muscular Dystrophy, Duchenne

    phase 3 small molecule terminated

    3 trials

  2. Ataluren

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    9 trials

  3. Ataluren

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  4. Ataluren (PTC124®)

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  5. Deflazacort

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    3 trials

  6. Deflazacort

    PTC THERAPEUTICS, INC.

    Limb-Girdle Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  7. PTC299

    PTC THERAPEUTICS, INC.

    Pneumonia

    phase 3 small molecule terminated

    1 trial

  8. PTC923

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    2 trials

  9. PTC923, PTC923

    PTC THERAPEUTICS, INC.

    Metabolic Disorders - Phenylketonuria

    phase 3 small molecule active

    1 trial

  10. PTC923-PKU-301

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  11. PTC923-PKU-401

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  12. Sepiapterin

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  13. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 small molecule terminated

    2 trials

  14. Vatiquinone

    PTC THERAPEUTICS, INC.

    Friedreich ataxia

    phase 3 small molecule active

    1 trial

  15. Vatiquinone

    PTC THERAPEUTICS, INC.

    Friedreich Ataxia

    phase 3 small molecule active

    3 trials

  16. Vatiquinone

    PTC THERAPEUTICS, INC.

    Inherited Mitochondrial Disease

    phase 3 small molecule completed

    1 trial

  17. Vatiquinone

    PTC THERAPEUTICS, INC.

    Mitochondrial Diseases

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does PTC THERAPEUTICS have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.